Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure.
Intracardiac accumulation of lipid and related intermediates (e.g., ceramide) is associated with cardiac dysfunction and may contribute to the progression of heart failure (HF). Overexpression of nuclear receptor peroxisome proliferator-activated receptor-alpha (PPARalpha) increases intramyocellular ceramide and left ventricular (LV) dysfunction. We tested the hypothesis that activation of fatty acid metabolism with fat feeding or a PPARalpha agonist increases myocardial triglyceride and/or ceramide and exacerbates LV dysfunction in HF. Rats with infarct-induced HF (n = 38) or sham-operated rats (n = 10) were either untreated (INF, n = 10), fed a high-fat diet (45% kcal fat, INF + Fat, n = 15), or fed the PPARalpha agonist fenofibrate (150 mg.kg(-1).day(-1), INF + Feno, n = 13) for 12 wk. LV ejection fraction was significantly reduced with HF (49 +/- 6%) compared with sham operated (86 +/- 2%) with no significant differences in ejection fraction (or other functional or hemodynamic measures) among the three infarcted groups. Treatment with the PPARalpha agonist resulted in LV hypertrophy (24% increase in LV/body mass ratio) and induced mRNAs encoding for PPARalpha-regulated genes, as well as protein expression and activity of medium chain acyl-CoA dehydrogenase (compared with INF and INF + Fat groups). Myocardial ceramide content was elevated in the INF group compared with sham-operated rats, with no further change in the INF + Fat or INF + Feno groups. Myocardial triglyceride was unaffected by infarction but increased in the INF + Fat group. In conclusion, LV dysfunction and dilation are not worsened despite upregulation of the fatty acid metabolic pathway and LV hypertrophy or accumulation of myocardial triglyceride in the rat infarct model of HF.
Morgan
Eric E
EE
Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH 44106-4970, USA.
Rennison
Julie H
JH
Young
Martin E
ME
McElfresh
Tracy A
TA
Kung
Theodore A
TA
Tserng
Kou-Yi
KY
Hoit
Brian D
BD
Stanley
William C
WC
Chandler
Margaret P
MP
D000818:Animals; D002518:Ceramides / Q000378:metabolism; D004041:Dietary Fats / Q000378:metabolism*; D004195:Disease Models, Animal; D005247:Feeding Behavior / Q000502:physiology; D011345:Fenofibrate / Q000008:administration & dosage; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D047493:PPAR alpha / Q000819:agonists / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*
D002518:Ceramides; D004041:Dietary Fats; D000960:Hypolipidemic Agents; D047493:PPAR alpha; D011345:Fenofibrate